Publications by authors named "Mohammed Hamidou"
Objective: Anti-transcription intermediary factor 1γ (anti-TIF1γ) antibodies are the main predictors of cancer in dermatomyositis (DM). Yet, a substantial proportion of anti-TIF1γ-positive DM patients do not develop cancer. This study was undertaken to identify biomarkers to better evaluate the risk of cancer and mortality in DM.
View Article and Find Full Text PDFObjective: We describe myelodysplastic syndrome (MDS)-associated systemic inflammatory and autoimmune diseases (SIADs), their treatments and outcomes and the impact of SIADs on overall survival in a French multicentre retrospective study.
Methods: In this study, 123 patients with MDS and SIADs were analysed.
Results: Mean age was 70 years (s.
Article Synopsis
- Pulmonary fibrosis (PF) is an uncommon but severe complication found in patients with ANCA-associated vasculitis (AAV), especially in those with microscopic polyangiitis (MPA), and typically has a worse prognosis.
- In a study of 49 patients with PF and AAV, the majority were diagnosed with MPA, and 45% had PF appear before vasculitis symptoms, with usual interstitial pneumonia being the most common radiological pattern.
- Survival rates were higher in patients receiving combined therapy with glucocorticoids and immunosuppressants like cyclophosphamide, suggesting better treatment outcomes compared to glucocorticoids alone, emphasizing the importance of tailored therapy for these
Mast cell leukemia (MCL) is a rare and aggressive disease with poor prognosis and short survival time. D816V c-KIT mutation is the most frequent molecular abnormality and plays a crucial role in the pathogenesis and development of the disease. Thus, comprehensive diagnostic investigations and molecular studies should be carefully carried out to facilitate the therapeutic choice.
View Article and Find Full Text PDFObjectives: Two types of anti-Ro/SSA antibodies have been described, anti-SSA-52 kDa (aSSA52) and anti-SSA-60 kDa (aSSA60), each specific to different antigens. However, conflicting data exist concerning the involvement of the aSSA52 in autoimmune diseases (ADs). We therefore determined the clinical significance of these antibodies in patients displaying aSSA52, but not aSSA60.
View Article and Find Full Text PDF